CN105338977B - 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 - Google Patents

艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 Download PDF

Info

Publication number
CN105338977B
CN105338977B CN201480036218.0A CN201480036218A CN105338977B CN 105338977 B CN105338977 B CN 105338977B CN 201480036218 A CN201480036218 A CN 201480036218A CN 105338977 B CN105338977 B CN 105338977B
Authority
CN
China
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
purposes
eribulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480036218.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105338977A (zh
Inventor
野本研
野本研一
吴佳怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN105338977A publication Critical patent/CN105338977A/zh
Application granted granted Critical
Publication of CN105338977B publication Critical patent/CN105338977B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
CN201480036218.0A 2013-06-26 2014-06-26 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 Active CN105338977B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839542P 2013-06-26 2013-06-26
US61/839542 2013-06-26
PCT/JP2014/067723 WO2014208774A1 (en) 2013-06-26 2014-06-26 Use of eribulin and lenvatinib as combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
CN105338977A CN105338977A (zh) 2016-02-17
CN105338977B true CN105338977B (zh) 2018-10-16

Family

ID=51210708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480036218.0A Active CN105338977B (zh) 2013-06-26 2014-06-26 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途

Country Status (12)

Country Link
US (1) US9549922B2 (enExample)
EP (1) EP3013335B1 (enExample)
JP (1) JP6404242B2 (enExample)
KR (1) KR102265952B1 (enExample)
CN (1) CN105338977B (enExample)
AU (1) AU2014299699B2 (enExample)
BR (1) BR112015029386B1 (enExample)
CA (1) CA2915005C (enExample)
ES (1) ES2705698T3 (enExample)
IL (1) IL242386B (enExample)
RU (1) RU2672585C2 (enExample)
WO (1) WO2014208774A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
EP3449921B1 (en) * 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
CN105832732A (zh) * 2016-05-30 2016-08-10 青岛云天生物技术有限公司 一种用于胃癌治疗的药物组合物及其应用
ES2932832T3 (es) * 2017-01-02 2023-01-26 Yonsung Fine Chemical Co Ltd Intermedio de producción de mesilato de eribulina, y método para producir el mismo
RU2750539C2 (ru) * 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN107973804B (zh) * 2017-11-29 2020-07-03 戊言医药科技（上海）有限公司 艾瑞布林中间体的合成方法
MA51570A (fr) 2018-01-10 2020-11-18 Eisai R&D Man Co Ltd Polythérapies pour le traitement du carcinome hépatocellulaire
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN114028394A (zh) * 2021-05-21 2022-02-11 中山大学 低剂量仑伐替尼在制备治疗肝癌的药物中的用途
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129100A1 (en) * 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012166899A2 (en) * 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
EP1481678A4 (en) 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
PL1698623T3 (pl) 2003-12-25 2015-08-31 Eisai R&D Man Co Ltd Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
PL2522663T3 (pl) * 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007052849A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
AU2008279027B8 (en) * 2007-07-25 2014-03-06 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
EP2578576B9 (en) 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
JP5399926B2 (ja) 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
SG182612A1 (en) 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US20120077837A1 (en) 2010-09-24 2012-03-29 Eisai R&D Management Co., Ltd. Anti-tumor agent
JP2014508165A (ja) * 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012154935A1 (en) 2011-05-12 2012-11-15 Eisai R&D Management Co., Ltd. Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
SG11201607298QA (en) 2014-03-03 2016-09-29 Eisai R&D Man Co Ltd Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
KR20170039096A (ko) 2014-05-28 2017-04-10 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료에 있어서 에리불린의 용도
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
JP6644479B2 (ja) 2014-06-24 2020-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129100A1 (en) * 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012166899A2 (en) * 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Also Published As

Publication number Publication date
CN105338977A (zh) 2016-02-17
CA2915005C (en) 2021-12-28
IL242386B (en) 2019-06-30
KR102265952B1 (ko) 2021-06-16
EP3013335B1 (en) 2018-11-07
RU2672585C2 (ru) 2018-11-16
CA2915005A1 (en) 2014-12-31
BR112015029386A8 (pt) 2020-03-17
JP6404242B2 (ja) 2018-10-10
BR112015029386B1 (pt) 2023-11-14
AU2014299699B2 (en) 2019-10-10
EP3013335A1 (en) 2016-05-04
ES2705698T3 (es) 2019-03-26
US9549922B2 (en) 2017-01-24
BR112015029386A2 (pt) 2017-07-25
JP2016528162A (ja) 2016-09-15
US20150005343A1 (en) 2015-01-01
RU2016102158A (ru) 2017-07-31
AU2014299699A1 (en) 2015-12-10
WO2014208774A1 (en) 2014-12-31
KR20160023816A (ko) 2016-03-03

Similar Documents

Publication Publication Date Title
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
US10238630B2 (en) Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
ES2808781T3 (es) Combinaciones de moduladores duales de IRS/STAT3 y agentes anticancerígenos para el tratamiento del cáncer
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
ES2902665T3 (es) Tratamiento del cáncer con combinación de plinabulina y taxano
TW201625240A (zh) 醫藥組成物
CA3137204A1 (en) Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
BR112017024126B1 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
WO2019032769A1 (en) POLYTHERAPIES COMPRISING HDAC INHIBITORS AND TUBULIN INHIBITORS
KR20220007146A (ko) 연부조직 육종의 조합 치료에 사용되는 퀴놀린 유도체
JP6644479B2 (ja) がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
WO2021114089A1 (en) Methods of using crocetin in treating solid tumors
EP4640218A1 (en) Use of sultam compound in treating biliary tract cancer
CN117769416A (zh) Bak激活剂、药物组合物和在治疗癌症中的用途
CA3141072A1 (en) Methods and uses for treating cancer
KR20140129091A (ko) 카바지탁셀의 신규한 소아과 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant